Nevro (NVRO) announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1 SI Joint Fusion System, a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. Nevro1’s performance also showed that it is equivalent in osteopenic bone when compared to a lateral triangular rod system in healthy bone. Results concluded: Nevro1 and the lateral triangular rods produced equivalent motion reduction in all motion planes. Posterolateral cylindrical threaded implant produced less motion reduction than Nevro1 and lateral implants in flexion-extension. Using Nevro1 for the treatment of SI joint-related pain allows for the most surface area for fusion, which provides a significantly better opportunity for robust SI joint arthrodesis.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks